Enara Bio’s Strategic Collaboration and Licensing Agreement with Boehringer Ingelheim

Goodwin Procter LLP advised Enara Bio on the deal.

Enara Bio announced its strategic collaboration and licensing agreement with Boehringer Ingelheim to research and develop novel targeted cancer immunotherapies, leveraging Enara Bio’s Dark Antigen™ discovery platform.

Enara Bio (formerly Ervaxx) is a science-led company targeting the T-cell/cancer-cell interface (the “immune synapse”) to develop new targeted cancer immunotherapies designed to treat a broad patient population. Enara Bio’s proprietary Dark Antigen Platform Technology (EDAPT™) will be used to discover and validate novel Dark Antigens in up to three tumor types in the lung and gastrointestinal cancer space.

Under the agreement, Enara Bio is eligible to receive an upfront payment, together with research/preclinical milestones and licensing fees for each tumor type that is explored. Enara Bio is also eligible to receive more than EUR 876 million in clinical, regulatory and commercial milestones, in addition to royalties on future product sales.

The Goodwin team was led by Emily Beman, Shivani Suhag, and Noelle Dubiansky (Picture), with invaluable assistance from Sabrina Poulos, Allyson Maur, William Weintraub, and Robert Carroll.

Involved fees earner: Emily Beman – Goodwin Procter; Robert Carroll – Goodwin Procter; Noelle Dubiansky – Goodwin Procter; Allyson Maur – Goodwin Procter; Sabrina Poulos – Goodwin Procter; Shivani Suhag – Goodwin Procter; William Weintraub – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: Enara Bio;


Author: Ambrogio Visconti